The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease with severe itch. The eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) are reported to reflect itch or the severity of AD. We examined i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/6/2201 |
| _version_ | 1797611032426840064 |
|---|---|
| author | Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda |
| author_facet | Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda |
| author_sort | Teppei Hagino |
| collection | DOAJ |
| description | Atopic dermatitis (AD) is a chronic inflammatory skin disease with severe itch. The eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) are reported to reflect itch or the severity of AD. We examined if these parameters may act as indicators for therapeutic effects of the Janus kinase 1 inhibitor upadacitinib for patients with AD in real-world clinical practice. Between August 2021 and September 2023, 65 Japanese patients (aged ≥ 12 years) with moderate to severe AD were treated with 15 mg/day of oral upadacitinib, plus twice daily topical corticosteroids. Before treatment, the baseline ELR, NLR, MLR, and PLR levels positively correlated with the eczema area and severity index (EASI), while the baseline NLR and PLR levels positively correlated with the peak pruritus-numerical rating scale (PP-NRS). After upadacitinib treatment, ELR and NLR remarkably decreased at week 4 and the reduced levels were maintained until week 24, in parallel with EASI and PP-NRS, while MLR and PLR transiently reduced at week 4, but returned to baseline levels after week 12. The percent reduction of ELR significantly correlated with the percent reductions of EASI and PP-NRS at weeks 4, 12, and 24 of upadacitinib treatment. ELR may act as an indicator for the improvement of clinical signs and itch by upadacitinib treatment in AD. |
| first_indexed | 2024-03-11T06:22:17Z |
| format | Article |
| id | doaj.art-a0a89757244746ad897b6f6a3ac7a1ad |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T06:22:17Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-a0a89757244746ad897b6f6a3ac7a1ad2023-11-17T11:49:29ZengMDPI AGJournal of Clinical Medicine2077-03832023-03-01126220110.3390/jcm12062201The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic DermatitisTeppei Hagino0Hidehisa Saeki1Eita Fujimoto2Naoko Kanda3Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai 270-1694, JapanDepartment of Dermatology, Nippon Medical School, Tokyo 113-8602, JapanFujimoto Dermatology Clinic, Funabashi 274-0063, JapanDepartment of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai 270-1694, JapanAtopic dermatitis (AD) is a chronic inflammatory skin disease with severe itch. The eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) are reported to reflect itch or the severity of AD. We examined if these parameters may act as indicators for therapeutic effects of the Janus kinase 1 inhibitor upadacitinib for patients with AD in real-world clinical practice. Between August 2021 and September 2023, 65 Japanese patients (aged ≥ 12 years) with moderate to severe AD were treated with 15 mg/day of oral upadacitinib, plus twice daily topical corticosteroids. Before treatment, the baseline ELR, NLR, MLR, and PLR levels positively correlated with the eczema area and severity index (EASI), while the baseline NLR and PLR levels positively correlated with the peak pruritus-numerical rating scale (PP-NRS). After upadacitinib treatment, ELR and NLR remarkably decreased at week 4 and the reduced levels were maintained until week 24, in parallel with EASI and PP-NRS, while MLR and PLR transiently reduced at week 4, but returned to baseline levels after week 12. The percent reduction of ELR significantly correlated with the percent reductions of EASI and PP-NRS at weeks 4, 12, and 24 of upadacitinib treatment. ELR may act as an indicator for the improvement of clinical signs and itch by upadacitinib treatment in AD.https://www.mdpi.com/2077-0383/12/6/2201atopic dermatitisupadacitinibeosinophil-to-lymphocyte ratioeczema area and severity indexpeak pruritus-numerical rating scale |
| spellingShingle | Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis Journal of Clinical Medicine atopic dermatitis upadacitinib eosinophil-to-lymphocyte ratio eczema area and severity index peak pruritus-numerical rating scale |
| title | The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis |
| title_full | The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis |
| title_fullStr | The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis |
| title_full_unstemmed | The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis |
| title_short | The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis |
| title_sort | eosinophil to lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis |
| topic | atopic dermatitis upadacitinib eosinophil-to-lymphocyte ratio eczema area and severity index peak pruritus-numerical rating scale |
| url | https://www.mdpi.com/2077-0383/12/6/2201 |
| work_keys_str_mv | AT teppeihagino theeosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis AT hidehisasaeki theeosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis AT eitafujimoto theeosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis AT naokokanda theeosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis AT teppeihagino eosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis AT hidehisasaeki eosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis AT eitafujimoto eosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis AT naokokanda eosinophiltolymphocyteratioactsasanindicatorforimprovementofclinicalsignsanditchbyupadacitinibtreatmentinatopicdermatitis |